Cargando…

An in vivo cis-Regulatory Screen at the Type 2 Diabetes Associated TCF7L2 Locus Identifies Multiple Tissue-Specific Enhancers

Genome-wide association studies (GWAS) have repeatedly shown an association between non-coding variants in the TCF7L2 locus and risk for type 2 diabetes (T2D), implicating a role for cis-regulatory variation within this locus in disease etiology. Supporting this hypothesis, we previously localized c...

Descripción completa

Detalles Bibliográficos
Autores principales: Savic, Daniel, Bell, Graeme I., Nobrega, Marcelo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349716/
https://www.ncbi.nlm.nih.gov/pubmed/22590553
http://dx.doi.org/10.1371/journal.pone.0036501
_version_ 1782232551826391040
author Savic, Daniel
Bell, Graeme I.
Nobrega, Marcelo A.
author_facet Savic, Daniel
Bell, Graeme I.
Nobrega, Marcelo A.
author_sort Savic, Daniel
collection PubMed
description Genome-wide association studies (GWAS) have repeatedly shown an association between non-coding variants in the TCF7L2 locus and risk for type 2 diabetes (T2D), implicating a role for cis-regulatory variation within this locus in disease etiology. Supporting this hypothesis, we previously localized complex regulatory activity to the TCF7L2 T2D-associated interval using an in vivo bacterial artificial chromosome (BAC) enhancer-trapping reporter strategy. To follow-up on this broad initial survey of the TCF7L2 regulatory landscape, we performed a fine-mapping enhancer scan using in vivo mouse transgenic reporter assays. We functionally interrogated approximately 50% of the sequences within the T2D-associated interval, utilizing sequence conservation within this 92-kb interval to determine the regulatory potential of all evolutionary conserved sequences that exhibited conservation to the non-eutherian mammal opossum. Included in this study was a detailed functional interrogation of sequences spanning both protective and risk alleles of single nucleotide polymorphism (SNP) rs7903146, which has exhibited allele-specific enhancer function in pancreatic beta cells. Using these assays, we identified nine segments regulating various aspects of the TCF7L2 expression profile and that constitute nearly 70% of the sequences tested. These results highlight the regulatory complexity of this interval and support the notion that a TCF7L2 cis-regulatory disruption leads to T2D predisposition.
format Online
Article
Text
id pubmed-3349716
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33497162012-05-15 An in vivo cis-Regulatory Screen at the Type 2 Diabetes Associated TCF7L2 Locus Identifies Multiple Tissue-Specific Enhancers Savic, Daniel Bell, Graeme I. Nobrega, Marcelo A. PLoS One Research Article Genome-wide association studies (GWAS) have repeatedly shown an association between non-coding variants in the TCF7L2 locus and risk for type 2 diabetes (T2D), implicating a role for cis-regulatory variation within this locus in disease etiology. Supporting this hypothesis, we previously localized complex regulatory activity to the TCF7L2 T2D-associated interval using an in vivo bacterial artificial chromosome (BAC) enhancer-trapping reporter strategy. To follow-up on this broad initial survey of the TCF7L2 regulatory landscape, we performed a fine-mapping enhancer scan using in vivo mouse transgenic reporter assays. We functionally interrogated approximately 50% of the sequences within the T2D-associated interval, utilizing sequence conservation within this 92-kb interval to determine the regulatory potential of all evolutionary conserved sequences that exhibited conservation to the non-eutherian mammal opossum. Included in this study was a detailed functional interrogation of sequences spanning both protective and risk alleles of single nucleotide polymorphism (SNP) rs7903146, which has exhibited allele-specific enhancer function in pancreatic beta cells. Using these assays, we identified nine segments regulating various aspects of the TCF7L2 expression profile and that constitute nearly 70% of the sequences tested. These results highlight the regulatory complexity of this interval and support the notion that a TCF7L2 cis-regulatory disruption leads to T2D predisposition. Public Library of Science 2012-05-10 /pmc/articles/PMC3349716/ /pubmed/22590553 http://dx.doi.org/10.1371/journal.pone.0036501 Text en Savic et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Savic, Daniel
Bell, Graeme I.
Nobrega, Marcelo A.
An in vivo cis-Regulatory Screen at the Type 2 Diabetes Associated TCF7L2 Locus Identifies Multiple Tissue-Specific Enhancers
title An in vivo cis-Regulatory Screen at the Type 2 Diabetes Associated TCF7L2 Locus Identifies Multiple Tissue-Specific Enhancers
title_full An in vivo cis-Regulatory Screen at the Type 2 Diabetes Associated TCF7L2 Locus Identifies Multiple Tissue-Specific Enhancers
title_fullStr An in vivo cis-Regulatory Screen at the Type 2 Diabetes Associated TCF7L2 Locus Identifies Multiple Tissue-Specific Enhancers
title_full_unstemmed An in vivo cis-Regulatory Screen at the Type 2 Diabetes Associated TCF7L2 Locus Identifies Multiple Tissue-Specific Enhancers
title_short An in vivo cis-Regulatory Screen at the Type 2 Diabetes Associated TCF7L2 Locus Identifies Multiple Tissue-Specific Enhancers
title_sort in vivo cis-regulatory screen at the type 2 diabetes associated tcf7l2 locus identifies multiple tissue-specific enhancers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349716/
https://www.ncbi.nlm.nih.gov/pubmed/22590553
http://dx.doi.org/10.1371/journal.pone.0036501
work_keys_str_mv AT savicdaniel aninvivocisregulatoryscreenatthetype2diabetesassociatedtcf7l2locusidentifiesmultipletissuespecificenhancers
AT bellgraemei aninvivocisregulatoryscreenatthetype2diabetesassociatedtcf7l2locusidentifiesmultipletissuespecificenhancers
AT nobregamarceloa aninvivocisregulatoryscreenatthetype2diabetesassociatedtcf7l2locusidentifiesmultipletissuespecificenhancers
AT savicdaniel invivocisregulatoryscreenatthetype2diabetesassociatedtcf7l2locusidentifiesmultipletissuespecificenhancers
AT bellgraemei invivocisregulatoryscreenatthetype2diabetesassociatedtcf7l2locusidentifiesmultipletissuespecificenhancers
AT nobregamarceloa invivocisregulatoryscreenatthetype2diabetesassociatedtcf7l2locusidentifiesmultipletissuespecificenhancers